

Nico van Zandwijk

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6417930/nico-van-zandwijk-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

228
papers

14,120
citations

67
h-index

113
g-index

320
ext. papers

15,514
ext. citations

5.2
avg, IF

5.96
L-index

#	Paper	IF	Citations
228	Asbestos and Zeolites: from A to Z via a Common Ion. <i>Chemical Research in Toxicology</i> , 2021 , 34, 936-951	4	2
227	Genomic and transcriptional alterations in first-line chemotherapy exert a potentially unfavorable influence on subsequent immunotherapy in NSCLC. <i>Theranostics</i> , 2021 , 11, 7092-7109	12.1	3
226	Anti-Mesothelin CAR T cell therapy for malignant mesothelioma. <i>Biomarker Research</i> , 2021 , 9, 11	8	13
225	Hitting the Bull's-Eye: Mesothelin's Role as a Biomarker and Therapeutic Target for Malignant Pleural Mesothelioma. <i>Cancers</i> , 2021 , 13,	6.6	1
224	Asbestos-related cancers: the Hidden Killer Remains a global threat. <i>Expert Review of Anticancer Therapy</i> , 2020 , 20, 271-278	3.5	12
223	Manipulating microRNAs for the Treatment of Malignant Pleural Mesothelioma: Past, Present and Future. <i>Frontiers in Oncology</i> , 2020 , 10, 105	5.3	17
222	Covalent binding of molecules to plasma immersion ion implantation-activated microparticles for delivery into cells. <i>Engineering Reports</i> , 2020 , 2, e12087	1.2	1
221	Zeolites ameliorate asbestos toxicity in a transgenic model of malignant mesothelioma. <i>FASEB BioAdvances</i> , 2019 , 1, 550-560	2.8	3
220	Patterns of care and survival of older patients with malignant pleural mesothelioma. <i>Journal of Geriatric Oncology</i> , 2019 , 10, 573-576	3.6	1
219	Asbestos and the Pathophysiology of Mesothelioma 2019 , 19-33		1
218	Transcriptional suppression of the miR-15/16 family by c-Myc in malignant pleural mesothelioma. <i>Oncotarget</i> , 2019 , 10, 4125-4138	3.3	8
217	Tumour suppressor microRNAs contribute to drug resistance in malignant pleural mesothelioma by targeting anti-apoptotic pathways. 2019 , 2, 1193-1206		2
216	Awareness: potential toxicities of carbon nanotubes. <i>Translational Lung Cancer Research</i> , 2019 , 8, S471-S472	4.4	4
215	The Immune Microenvironment in Mesothelioma: Mechanisms of Resistance to Immunotherapy. <i>Frontiers in Oncology</i> , 2019 , 9, 1366	5.3	29
214	Dysregulated Expression of the MicroRNA miR-137 and Its Target YBX1 Contribute to the Invasive Characteristics of Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 258-272	8.9	29
213	FGF2 and EGF induce epithelial-mesenchymal transition in malignant pleural mesothelioma cells via a MAPKinase/MMP1 signal. <i>Carcinogenesis</i> , 2018 , 39, 534-545	4.6	18
212	A link between the fibroblast growth factor axis and the miR-16 family reveals potential new treatment combinations in mesothelioma. <i>Molecular Oncology</i> , 2018 , 12, 58-73	7.9	18

211 Chemoprevention of Lung Cancer and Management of Early Lung Cancer **2018**, 69-81.e5

210 Response to "An innovative mesothelioma treatment based on mir-16 mimic loaded EGFR targeted minicells (TargomiRs)". *Translational Lung Cancer Research*, **2018**, 7, S60-S61 4.4 6

209 A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group. *Journal of Thoracic Disease*, **2018**, 10, 3909-3921 2.6 24

208 Geographic and socioeconomic factors in patients with malignant pleural mesothelioma in New South Wales and their impact upon clinical outcomes. *Respirology*, **2017**, 22, 978-985 3.6 5

207 OA02.01 The microRNA-15/16 Family Regulates Tumor Cell Growth via Fibroblast Growth Factor Signals in Malignant Pleural Mesothelioma. *Journal of Thoracic Oncology*, **2017**, 12, S246 8.9 2

206 OA22.06 Refinement of the Prognostic miR-Score for Use in Diagnostic Specimens from Chemo-Naïve Malignant Pleural Mesothelioma Patients. *Journal of Thoracic Oncology*, **2017**, 12, S332 8.9 2

205 Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study. *Lancet Oncology*, **2017**, 18, 1386-1396 21.7 330

204 Management of Progressive Pulmonary Nodules Found during and outside of CT Lung Cancer Screening Studies. *Journal of Thoracic Oncology*, **2017**, 12, 1755-1765 8.9 6

203 Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma. *Journal of Thoracic Oncology*, **2017**, 12, 1421-1433 8.9 97

202 The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC. *Journal of Thoracic Oncology*, **2017**, 12, 194-207 8.9 132

201 The analysis of novel microRNA mimic sequences in cancer cells reveals lack of specificity in stem-loop RT-qPCR-based microRNA detection. *BMC Research Notes*, **2017**, 10, 600 2.3 5

200 Estimation of the global burden of mesothelioma deaths from incomplete national mortality data. *Occupational and Environmental Medicine*, **2017**, 74, 851-858 2.1 84

199 KCa1.1, a calcium-activated potassium channel subunit alpha 1, is targeted by miR-17-5p and modulates cell migration in malignant pleural mesothelioma. *Molecular Cancer*, **2016**, 15, 44 42.1 36

198 Circulating activin A is a novel prognostic biomarker in malignant pleural mesothelioma - A multi-institutional study. *European Journal of Cancer*, **2016**, 63, 64-73 7.5 17

197 Incidence and survival trends for malignant pleural and peritoneal mesothelioma, Australia, 1982-2009. *Occupational and Environmental Medicine*, **2016**, 73, 187-94 2.1 34

196 A proteomics-based approach identifies secreted protein acidic and rich in cysteine as a prognostic biomarker in malignant pleural mesothelioma. *British Journal of Cancer*, **2016**, 114, 524-31 8.7 15

195 Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy. *ESMO Open*, **2016**, 1, e000118 6 4

194 Using a multidisciplinary approach to combat the burden of asbestos-related disease. *Medical Journal of Australia*, **2016**, 204, 52 4

193	Patterns in the incidence, mortality and survival of malignant pleural and peritoneal mesothelioma, New South Wales, 1972-2009. <i>Australian and New Zealand Journal of Public Health</i> , 2016 , 40, 255-62	2.3	14
192	Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer. <i>Epigenomics</i> , 2016 , 8, 1079-85	4.4	124
191	Estimating the incidence of malignant mesothelioma in Vietnam: a pilot descriptive cancer registration study. <i>International Journal of Occupational and Environmental Health</i> , 2016 , 22, 167-72		2
190	MicroRNA gene expression signatures in long-surviving malignant pleural mesothelioma patients. <i>Genomics Data</i> , 2016 , 9, 44-9		4
189	Malignant mesothelioma in Australia 2015: Current incidence and asbestos exposure trends. <i>Journal of Toxicology and Environmental Health - Part B: Critical Reviews</i> , 2016 , 19, 173-189	8.6	23
188	A Significant Metabolic and Radiological Response after a Novel Targeted MicroRNA-based Treatment Approach in Malignant Pleural Mesothelioma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015 , 191, 1467-9	10.2	54
187	MiR-score: a novel 6-microRNA signature that predicts survival outcomes in patients with malignant pleural mesothelioma. <i>Molecular Oncology</i> , 2015 , 9, 715-26	7.9	54
186	Estimation of an optimal chemotherapy utilization rate for malignant pleural mesothelioma: an evidence-based benchmark for cancer care. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2015 , 11, 85-92	1.9	4
185	Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis. <i>British Journal of Cancer</i> , 2015 , 113, 963-9	8.7	48
184	MesomiR 1: A Phase I study of TargomiRs in patients with refractory malignant pleural mesothelioma (MPM) and lung cancer (NSCLC). <i>Annals of Oncology</i> , 2015 , 26, ii16	10.3	25
183	Abstract 3976: Targeted delivery of a synthetic microRNA-based mimic as an approach to cancer therapy 2015 ,		14
182	miR-193a-3p is a potential tumor suppressor in malignant pleural mesothelioma. <i>Oncotarget</i> , 2015 , 6, 23480-95	3.3	68
181	Comment on Existing prognostic models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma <i>British Journal of Cancer</i> , 2014 , 111, 2376	8.7	3
180	An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma. <i>British Journal of Cancer</i> , 2014 , 110, 510-9	8.7	37
179	Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales. <i>British Journal of Cancer</i> , 2014 , 111, 1860-9	8.7	52
178	Cilengitide inhibits attachment and invasion of malignant pleural mesothelioma cells through antagonism of integrins $\alpha 5 \beta 1$ and $\alpha 5 \beta 3$. <i>PLoS ONE</i> , 2014 , 9, e90374	3.7	23
177	Prognostic significance of circulating secreted protein acidic and rich in cysteine (SPARC) in malignant pleural mesothelioma (MPM).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 7580-7580	2.2	
176	Old and new prognostic factors in a series of 910 patients with malignant pleural mesothelioma (MPM).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 7586-7586	2.2	

175	Levels of plasma fibulin-3 and accuracy of identifying patients with malignant pleural mesothelioma.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e18543-e18543	2.2	
174	Use of cancer therapy at the end of life in patients with malignant pleural mesothelioma. <i>Supportive Care in Cancer</i> , 2013 , 21, 1879-84	3.9	8
173	Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers. <i>Journal of Clinical Pathology</i> , 2013 , 66, 847-53	3.9	74
172	Challenges and controversies in the diagnosis of malignant mesothelioma: Part 2. Malignant mesothelioma subtypes, pleural synovial sarcoma, molecular and prognostic aspects of mesothelioma, BAP1, aquaporin-1 and microRNA. <i>Journal of Clinical Pathology</i> , 2013 , 66, 854-61	3.9	38
171	Patterns of care for malignant pleural mesothelioma patients compensated by the Dust Diseases Board in New South Wales, Australia. <i>Internal Medicine Journal</i> , 2013 , 43, 402-10	1.6	15
170	Health-related quality of life and inflammatory markers in malignant pleural mesothelioma. <i>Supportive Care in Cancer</i> , 2013 , 21, 697-705	3.9	33
169	Excision repair cross complementation group 1 and thymidylate synthase expression in patients with mesothelioma. <i>Clinical Lung Cancer</i> , 2013 , 14, 164-71	4.9	8
168	Identification of recurrent FGFR3 fusion genes in lung cancer through kinome-centred RNA sequencing. <i>Journal of Pathology</i> , 2013 , 230, 270-6	9.4	94
167	Validation of prognostic factors in malignant pleural mesothelioma: a retrospective analysis of data from patients seeking compensation from the New South Wales Dust Diseases Board. <i>Clinical Lung Cancer</i> , 2013 , 14, 70-7	4.9	48
166	Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma. <i>Annals of Oncology</i> , 2013 , 24, 3128-35	10.3	167
165	Immunohistochemistry in the diagnosis of malignant pleural mesothelioma: trends in Australia and a literature review. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2013 , 9, 273-9	1.9	6
164	Does miR-1 play a role in malignant pleural mesothelioma development and progression?. <i>Chest</i> , 2013 , 144, 1971	5.3	
163	ZIC1 is silenced and has tumor suppressor function in malignant pleural mesothelioma. <i>Journal of Thoracic Oncology</i> , 2013 , 8, 1317-28	8.9	25
162	Cell-free microRNAs: potential biomarkers in need of standardized reporting. <i>Frontiers in Genetics</i> , 2013 , 4, 56	4.5	53
161	The Impact of Hemolysis on Cell-Free microRNA Biomarkers. <i>Frontiers in Genetics</i> , 2013 , 4, 94	4.5	211
160	Long non coding RNAs (lncRNAs) are dysregulated in Malignant Pleural Mesothelioma (MPM). <i>PLoS ONE</i> , 2013 , 8, e70940	3.7	28
159	Clinical practice guidelines for malignant pleural mesothelioma. <i>Journal of Thoracic Disease</i> , 2013 , 5, 724-5	2.6	4
158	Guidelines for the diagnosis and treatment of malignant pleural mesothelioma. <i>Journal of Thoracic Disease</i> , 2013 , 5, E254-307	2.6	132

157	A novel microRNA-based treatment approach for malignant pleural mesothelioma.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 7586-7586	2.2	
156	Increased circulating miR-625-3p: a potential biomarker for patients with malignant pleural mesothelioma. <i>Journal of Thoracic Oncology</i> , 2012 , 7, 1184-91	8.9	95
155	The ticking time-bomb of asbestos: its insidious role in the development of malignant mesothelioma. <i>Critical Reviews in Oncology/Hematology</i> , 2012 , 84, 200-12	7	42
154	A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer. <i>Annals of Oncology</i> , 2012 , 23, 72-77	10.3	97
153	Radical surgery for malignant pleural mesothelioma: have we identified the appropriate selection tools?. <i>Annals of Cardiothoracic Surgery</i> , 2012 , 1, 481-6	4.7	3
152	Inflammation in malignant mesothelioma - friend or foe?. <i>Annals of Cardiothoracic Surgery</i> , 2012 , 1, 516-27	2.7	21
151	Second-line erlotinib in patients with advanced non-small-cell lung cancer: subgroup analyses from the TRUST study. <i>Lung Cancer</i> , 2011 , 74, 274-9	5.9	27
150	The MARS feasibility trial: conclusions not supported by data. <i>Lancet Oncology</i> , 2011 , 12, 1093-4; author reply 1094-5	21.7	103
149	Haemolysis during sample preparation alters microRNA content of plasma. <i>PLoS ONE</i> , 2011 , 6, e24145	3.7	380
148	Accuracy of diagnostic biopsy for the histological subtype of malignant pleural mesothelioma. <i>Journal of Thoracic Oncology</i> , 2011 , 6, 602-5	8.9	47
147	Validation of tissue microarray technology in malignant pleural mesothelioma. <i>Pathology</i> , 2011 , 43, 128-33	3.8	24
146	Low calretinin expression and high neutrophil-to-lymphocyte ratio are poor prognostic factors in patients with malignant mesothelioma undergoing extrapleural pneumonectomy. <i>Journal of Thoracic Oncology</i> , 2011 , 6, 1923-9	8.9	71
145	Validation of a minimal panel of antibodies for the diagnosis of malignant pleural mesothelioma. <i>Pathology</i> , 2011 , 43, 313-7	1.6	14
144	Molecular biomarkers in malignant mesothelioma: state of the art. <i>Pathology</i> , 2011 , 43, 201-12	1.6	14
143	Circulating microRNAs: Association with disease and potential use as biomarkers. <i>Critical Reviews in Oncology/Hematology</i> , 2011 , 80, 193-208	7	372
142	Examining the relationships among health-related quality-of-life indicators in cancer patients participating in clinical trials: a pooled study of baseline EORTC QLQ-C30 data. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2011 , 11, 587-99	2.2	10
141	Malignant mesothelioma. <i>Internal Medicine Journal</i> , 2010 , 40, 742-50	1.6	25
140	High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. <i>Clinical Cancer Research</i> , 2010 , 16, 5805-13	12.9	238

139	Reply to L.H. de Lima Araujo et al. <i>Journal of Clinical Oncology</i> , 2010 , 28, e26-e26	2.2	
138	Surgery after induction chemotherapy in stage IIIA-N2 non-small cell lung cancer: why pneumonectomy should be avoided. <i>Lung Cancer</i> , 2010 , 68, 222-7	5.9	21
137	Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study. <i>Journal of Thoracic Oncology</i> , 2010 , 5, 1616-22	8.9	106
136	Differential diagnosis of pulmonary carcinoma following head and neck cancer by genetic analysis. <i>Clinical Cancer Research</i> , 2009 , 15, 980-5	12.9	15
135	An immune response enriched 72-gene prognostic profile for early-stage non-small-cell lung cancer. <i>Clinical Cancer Research</i> , 2009 , 15, 284-90	12.9	123
134	Survival after surgical resection of pulmonary metastases and second primary squamous cell lung carcinomas in head and neck cancer. <i>Head and Neck</i> , 2009 , 31, 220-6	4.2	19
133	Immunotherapy in non-small-cell lung carcinoma: from inflammation to vaccination. <i>Clinical Lung Cancer</i> , 2009 , 10, 99-105	4.9	14
132	Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 2038-45	2.2	125
131	Results of combined modality treatment in patients with non-small-cell lung cancer of the superior sulcus and the rationale for surgical resection. <i>European Journal of Cardio-thoracic Surgery</i> , 2009 , 36, 741-6	3	28
130	Individualization of treatment in non-small cell lung cancer. <i>F1000 Medicine Reports</i> , 2009 , 1,		1
129	CT detected indeterminate pulmonary nodules in a chemoprevention trial of fluticasone. <i>Lung Cancer</i> , 2008 , 60, 57-61	5.9	20
128	Non-small cell lung carcinoma of the superior sulcus: favourable outcomes of combined modality treatment in carefully selected patients. <i>Lung Cancer</i> , 2008 , 59, 385-90	5.9	22
127	Neoadjuvant (induction) erlotinib response in stage IIIA non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2008 , 26, 4205-7	2.2	27
126	Integration of gene dosage and gene expression in non-small cell lung cancer, identification of HSP90 as potential target. <i>PLoS ONE</i> , 2008 , 3, e0001722	3.7	84
125	Influence of heat and moisture exchanger respiratory load on transcutaneous oxygenation in laryngectomized individuals: a randomized crossover study. <i>Head and Neck</i> , 2007 , 29, 1102-10	4.2	11
124	Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. <i>Journal of the National Cancer Institute</i> , 2007 , 99, 442-50	9.7	512
123	The influence of fluticasone inhalation on markers of carcinogenesis in bronchial epithelium. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007 , 175, 1061-5	10.2	18
122	Prognostic significance of ^{99m} Tc Hynic-rh-annexin V scintigraphy during platinum-based chemotherapy in advanced lung cancer. <i>Journal of Clinical Oncology</i> , 2007 , 25, 2534-9	2.2	79

121	M11-02: Chemoprevention 2007. <i>Journal of Thoracic Oncology</i> , 2007 , 2, S183-S184	8.9	
120	Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973). <i>European Journal of Cancer</i> , 2007 , 43, 114-21	7.5	144
119	EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer. <i>Annals of Oncology</i> , 2007 , 18, 99-103	10.3	116
118	Mapping of treatment-induced apoptosis in normal structures: 99mTc-Hynic-rh-annexin V SPECT and CT image fusion. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2006 , 33, 893-9	8.8	25
117	Relationship between cisplatin administration and the development of ototoxicity. <i>Journal of Clinical Oncology</i> , 2006 , 24, 918-24	2.2	118
116	The psychological impact of annual chest X-ray follow-up in head and neck cancer. <i>Acta Oto-Laryngologica</i> , 2006 , 126, 1315-20	1.6	5
115	Epidermal growth factor tyrosine kinase inhibitors (EGFR TKIs) and economics. <i>Lung Cancer</i> , 2006 , 51, 137-8	5.9	3
114	Quality assurance of thoracic radiotherapy in EORTC 08941: a randomised trial of surgery versus thoracic radiotherapy in patients with stage IIIA non-small-cell lung cancer (NSCLC) after response to induction chemotherapy. <i>European Journal of Cancer</i> , 2006 , 42, 1391-8	7.5	10
113	Docetaxel-based induction therapy prior to radiotherapy with or without docetaxel for non-small-cell lung cancer. <i>British Journal of Cancer</i> , 2006 , 94, 1375-82	8.7	23
112	The physiological rationale of heat and moisture exchangers in post-laryngectomy pulmonary rehabilitation: a review. <i>European Archives of Oto-Rhino-Laryngology</i> , 2006 , 263, 1-8	3.5	39
111	Chemoprevention in lung carcinogenesis--an overview. <i>European Journal of Cancer</i> , 2005 , 41, 1990-2002	7.5	12
110	Thalidomide in patients with malignant pleural mesothelioma. <i>Lung Cancer</i> , 2005 , 48, 291-6	5.9	85
109	Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. <i>Lung Cancer</i> , 2005 , 47, 69-80	5.9	243
108	Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial. <i>Lung Cancer</i> , 2005 , 50, 83-6	5.9	111
107	Phase I clinical and pharmacologic study of a 2-weekly administration of cisplatin and gemcitabine in patients with advanced non-small cell lung cancer. <i>Anti-Cancer Drugs</i> , 2005 , 16, 1029-36	2.4	7
106	Morbidity and mortality in the surgery arm of EORTC 08941 trial. <i>European Respiratory Journal</i> , 2005 , 26, 192-7	13.6	74
105	Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2005 , 23, 8362-70	2.2	221
104	Pulmonary squamous cell carcinoma following head and neck squamous cell carcinoma: metastasis or second primary?. <i>Clinical Cancer Research</i> , 2005 , 11, 6608-14	12.9	80

103	Gefitinib as a last treatment option for non-small-cell lung cancer: durable disease control in a subset of patients. <i>Annals of Oncology</i> , 2004 , 15, 786-92	10.3	47
102	Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel. <i>Annals of Oncology</i> , 2004 , 15, 419-26	10.3	121
101	Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. <i>Annals of Oncology</i> , 2004 , 15, 19-27	10.3	289
100	Bayesian pharmacokinetically guided dosing of paclitaxel in patients with non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2004 , 10, 2237-44	12.9	35
99	In vivo imaging of apoptosis by 99mTc-Annexin V scintigraphy: visual analysis in relation to treatment response. <i>Radiotherapy and Oncology</i> , 2004 , 72, 333-9	5.3	106
98	Adaptive inpatient dose escalation of cisplatin in combination with low-dose vp16 in patients with nonsmall cell lung cancer. <i>British Journal of Cancer</i> , 2003 , 88, 814-21	8.7	11
97	Chemoprevention of lung cancer: soon daily practice?. <i>Expert Review of Anticancer Therapy</i> , 2003 , 3, 91-83.5		2
96	Tolerability of gefitinib in patients receiving treatment in everyday clinical practice. <i>British Journal of Cancer</i> , 2003 , 89 Suppl 2, S9-14	8.7	25
95	The value of [18F]fluoro-2-deoxy-D-glucose positron emission tomography in the selection of patients with stage IIIA-N2 non-small cell lung cancer for combined modality treatment. <i>Lung Cancer</i> , 2003 , 39, 151-7	5.9	72
94	Consensus report IASLC workshop Bruges, September 2002: pretreatment minimal staging for non-small cell lung cancer. <i>Lung Cancer</i> , 2003 , 42 Suppl 1, S3-6	5.9	9
93	Chemoprevention of lung cancer: current status and future prospects. <i>Lung Cancer</i> , 2003 , 42 Suppl 1, S71-9	5.9	16
92	The value of chest computer tomography and cervical mediastinoscopy in the preoperative assessment of patients with malignant pleural mesothelioma. <i>Annals of Thoracic Surgery</i> , 2003 , 75, 1715-8; discussion 1718-9	2.7	61
91	The activity of raltitrexed (Tomudex) in malignant pleural mesothelioma: an EORTC phase II study (08992). <i>European Journal of Cancer</i> , 2003 , 39, 353-7	7.5	59
90	Randomized phase I clinical and pharmacologic study of weekly versus twice-weekly dose-intensive cisplatin and gemcitabine in patients with advanced non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2003 , 9, 3526-33	12.9	4
89	Ptprj is a candidate for the mouse colon-cancer susceptibility locus Scc1 and is frequently deleted in human cancers. <i>Nature Genetics</i> , 2002 , 31, 295-300	36.3	209
88	Randomized phase I and pharmacological study of weekly or 2-weekly gemcitabine and cisplatin in advanced non-small cell lung cancer. <i>British Journal of Clinical Pharmacology</i> , 2002 , 54, 554-555	3.8	78
87	Chemoprevention strategies for non-small cell lung cancer. <i>Current Opinion in Oncology</i> , 2002 , 14, 185-90.2		6
86	Cytoreductive surgery and intraoperative hyperthermic intrathoracic chemotherapy in patients with malignant pleural mesothelioma or pleural metastases of thymoma. <i>Chest</i> , 2002 , 121, 480-7	5.3	83

85	New methods for early diagnosis of lung cancer. <i>Lung Cancer</i> , 2002 , 38, S9-11	5.9	13
84	Second/third/fourth line therapy with tyrosine kinase inhibitors in NSCLC. <i>I Supplementi Di Tumori</i> , 2002 , 1, S37-8		
83	Intraoperative photodynamic therapy after pleuropneumonectomy in patients with malignant pleural mesothelioma: dose finding and toxicity results. <i>Chest</i> , 2001 , 120, 1167-74	5.3	75
82	Stratégie thérapeutique de chimiothérapie néoadjuvante du cancer bronchique non ^ petites cellules: interférence de la gemcitabine. <i>Anti-Cancer Drugs</i> , 2001 , 12, S15-S19	2.4	6
81	The prognostic significance of a previous malignancy in operable non-small cell lung cancer. <i>Lung Cancer</i> , 2001 , 32, 47-53	5.9	23
80	Neoadjuvant strategies for non-small cell lung cancer. <i>Lung Cancer</i> , 2001 , 34 Suppl 2, S145-50	5.9	24
79	A randomised phase II study of gemcitabine/cisplatin alone and with herceptin in patients with HER2-positive non-small cell lung cancer (nscl). <i>European Journal of Cancer</i> , 2001 , 37, S50	7.5	7
78	Gemcitabine and cisplatin as induction regimen for patients with biopsy-proven stage IIIA N2 non-small-cell lung cancer: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group (EORTC 08955). <i>Journal of Clinical Oncology</i> , 2001 , 19, 2170-74	2.2	131
77	EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the European Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups. <i>Journal of the National Cancer Institute</i> , 2000 , 92, 977-86	9.7	277
76	Teniposide sometimes effective in brain metastases from non-small cell lung cancer. <i>Journal of Neuro-Oncology</i> , 1999 , 41, 285-9	4.8	19
75	Differences in aromatic-DNA adduct levels between alveolar macrophages and subpopulations of white blood cells from smokers. <i>Carcinogenesis</i> , 1998 , 19, 819-25	4.6	69
74	Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. <i>Journal of Clinical Oncology</i> , 1998 , 16, 2133-41	2.2	237
73	Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre. <i>Journal of Clinical Oncology</i> , 1997 , 15, 317-29	2.2	152
72	Role of recombinant interferon-gamma maintenance in responding patients with small cell lung cancer. A randomised phase III study of the EORTC Lung Cancer Cooperative Group. <i>European Journal of Cancer</i> , 1997 , 33, 1759-66	7.5	45
71	Etoposide in malignant pleural mesothelioma: two phase II trials of the EORTC Lung Cancer Cooperative Group. <i>European Journal of Cancer</i> , 1997 , 33, 2211-5	7.5	45
70	Mutational activation of the K-ras oncogene and the effect of chemotherapy in advanced adenocarcinoma of the lung: a prospective study. <i>Journal of Clinical Oncology</i> , 1997 , 15, 285-91	2.2	78
69	Photodynamic therapy as adjuvant therapy in surgically treated pleural malignancies. <i>British Journal of Cancer</i> , 1997 , 76, 819-26	8.7	96
68	The toxicity of radiotherapy following high-dose chemotherapy with peripheral blood stem cell support in high-risk breast cancer: a preliminary analysis. <i>European Journal of Cancer</i> , 1996 , 32A, 1490-7	7.5	16

67	Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. <i>Journal of Clinical Oncology</i> , 1996 , 14, 814-20	2.2	173
66	Two schedules of teniposide with or without cisplatin in advanced non-small-cell lung cancer: a randomized study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. <i>Journal of Clinical Oncology</i> , 1996 , 14, 127-34	2.2	23
65	Recovery of overall and local lung function loss 18 months after irradiation for malignant lymphoma. <i>Journal of Clinical Oncology</i> , 1996 , 14, 1431-41	2.2	35
64	Oral ifosfamide/mesna versus intravenous ifosfamide/mesna in non-small-cell lung cancer: a randomized phase II trial of the EORTC lung cancer cooperative group. <i>Annals of Oncology</i> , 1996 , 7, 637-9	10.3	8
63	Treatment of metastatic non-small cell lung cancer. <i>Current Opinion in Oncology</i> , 1996 , 8, 120-5	4.2	19
62	Immunoscintigraphy of small-cell lung cancer xenografts with anti neural cell adhesion molecule monoclonal antibody, 123C3: improvement of tumour uptake by internalisation. <i>British Journal of Cancer</i> , 1996 , 73, 439-46	8.7	10
61	Value of resection of pulmonary metastases in head and neck cancer patients. <i>Head and Neck</i> , 1996 , 18, 311-6	4.2	89
60	Smokers and urinary genotoxins: Implications for selection of cohorts and modulation of endpoints in chemoprevention trials. <i>Journal of Cellular Biochemistry</i> , 1996 , 63, 92-98	4.7	11
59	Photodynamic therapy: a promising new modality for the treatment of cancer. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 1996 , 34, 3-12	6.7	220
58	Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group. <i>British Journal of Cancer</i> , 1996 , 74, 961-3	8.7	75
57	Radioimmunotherapy of small-cell lung cancer xenografts using 131I-labelled anti-NCAM monoclonal antibody 123C3. <i>Cancer Immunology, Immunotherapy</i> , 1995 , 41, 169-74	7.4	4
56	Teniposide for brain metastases of small-cell lung cancer: a phase II study. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. <i>Journal of Clinical Oncology</i> , 1995 , 13, 660-5	2.2	57
55	Tracheal obstruction after placement of a metal wire expandable stent (Wallstent). <i>Lung Cancer</i> , 1995 , 12, 77-80	5.9	6
54	Prognostic factors in NSCLC. Recent experiences. <i>Lung Cancer</i> , 1995 , 12 Suppl 1, S27-33	5.9	25
53	Estimation of overall pulmonary function after irradiation using dose-effect relations for local functional injury. <i>Radiotherapy and Oncology</i> , 1995 , 36, 15-23	5.3	88
52	N-acetylcysteine for lung cancer prevention. <i>Chest</i> , 1995 , 107, 1437-41	5.3	22
51	Heat and moisture exchangers as a treatment option in the post-operative rehabilitation of laryngectomized patients. <i>Clinical Otolaryngology</i> , 1995 , 20, 504-9	1.8	35
50	Effect of N-acetylcysteine on Photofrin-induced skin photosensitivity in patients. <i>Lasers in Surgery and Medicine</i> , 1995 , 16, 359-67	3.6	32

49	N-acetylcysteine (NAC) and glutathione (GSH): antioxidant and chemopreventive properties, with special reference to lung cancer. <i>Journal of Cellular Biochemistry</i> , 1995 , 22, 24-32	4.7	81
48	Radioimmunotherapy of small-cell lung cancer xenografts using ¹³¹ I-labelled anti-NCAM monoclonal antibody 123C3. <i>Cancer Immunology, Immunotherapy</i> , 1995 , 41, 169-174	7.4	3
47	Enhancement of interstitial photodynamic therapy by mitomycin C and EO9 in a mouse tumour model. <i>International Journal of Cancer</i> , 1994 , 56, 880-5	7.5	21
46	NCAM and lung cancer. <i>International Journal of Cancer</i> , 1994 , 8, 34-7	7.5	43
45	Partial protection of photodynamic-induced skin reactions in mice by N-acetylcysteine: a preclinical study. <i>Photochemistry and Photobiology</i> , 1994 , 59, 448-54	3.6	17
44	Chemoprevention of second primary tumours in head and neck cancer in Europe: EUROSCAN. <i>European Journal of Cancer Part B, Oral Oncology</i> , 1994 , 30B, 367-8		15
43	Dose-effect relations for local functional and structural changes of the lung after irradiation for malignant lymphoma. <i>Radiotherapy and Oncology</i> , 1994 , 32, 201-9	5.3	79
42	The EUROSCAN study: a progress report. <i>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</i> , 1993 , 14, 62-6	2.8	9
41	New treatment opportunities in non-small cell lung cancer. <i>Lung Cancer</i> , 1993 , 9, 109-116	5.9	5
40	A new method to determine dose-effect relations for local lung-function changes using correlated SPECT and CT data. <i>Radiotherapy and Oncology</i> , 1993 , 29, 110-6	5.3	62
39	Phase II study of vinorelbine (Navelbine) in previously treated small cell lung cancer patients. EORTC Lung Cancer Cooperative Group. <i>European Journal of Cancer</i> , 1993 , 29A, 1720-2	7.5	67
38	Pulmonary morbidity 10-18 years after irradiation for Hodgkin's disease. <i>European Journal of Cancer</i> , 1993 , 29A, 343-7	7.5	25
37	Improvements in respiratory and psychosocial functioning following total laryngectomy by the use of a heat and moisture exchanger. <i>Annals of Otolaryngology, Rhinology and Laryngology</i> , 1993 , 102, 878-83	2.1	65
36	Photodynamic therapy as an alternative treatment for surgery in a patient with lung cancer undergoing bone marrow transplantation. <i>Chest</i> , 1993 , 103, 1908-9	5.3	3
35	Improvements in the assessment of pulmonary function in laryngectomized patients. <i>Laryngoscope</i> , 1993 , 103, 1391-4	3.6	14
34	Pilot study on light dosimetry for endobronchial photodynamic therapy. <i>Photochemistry and Photobiology</i> , 1993 , 58, 92-9	3.6	34
33	Interaction of the bioreductive drug SR 4233 and photodynamic therapy using photofrin in a mouse tumor model. <i>International Journal of Radiation Oncology Biology Physics</i> , 1993 , 27, 665-70	4	9
32	Development of cylindrical diffusing fibres suitable for interstitial photodynamic therapy. <i>Lasers in Medical Science</i> , 1993 , 8, 93-98	3.1	2

31	Polycyclic aromatic hydrocarbon--DNA adducts in white blood cells from lung cancer patients: no correlation with adduct levels in lung. <i>Carcinogenesis</i> , 1992 , 13, 987-93	4.6	90
30	Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. <i>New England Journal of Medicine</i> , 1992 , 326, 524-30	59.2	1074
29	High dose rate brachytherapy improves resectability in squamous cell lung cancer. <i>Chest</i> , 1992 , 102, 308-93	9.3	16
28	A pilot study of photodynamic therapy in patients with inoperable non-small cell lung cancer. <i>European Journal of Cancer</i> , 1992 , 28A, 1370-3	7.5	37
27	Epirubicin in previously untreated patients with small cell lung cancer: a phase II study by the EORTC Lung Cancer Cooperative Group. <i>European Journal of Cancer</i> , 1992 , 28A, 1667-70	7.5	13
26	Chemoprevention in the management of oral cancer: EUROSCAN and other studies. <i>European Journal of Cancer Part B, Oral Oncology</i> , 1992 , 28B, 153-7		13
25	Epirubicin in malignant mesothelioma: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. <i>Journal of Clinical Oncology</i> , 1992 , 10, 824-8	2.2	58
24	High dose rate brachytherapy in patients with local recurrences after radiotherapy of non-small cell lung cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 1992 , 24, 551-3	4	63
23	The influence of a heat and moisture exchanger (HME) on the respiratory symptoms after total laryngectomy. <i>Clinical Otolaryngology</i> , 1991 , 16, 152-6	1.8	90
22	Activity of intrapleural recombinant gamma-interferon in malignant mesothelioma. <i>Cancer</i> , 1991 , 67, 2033-7	6.4	108
21	The need for immediate monitoring of treatment parameters and uniform assessment of patient data in clinical trials. A quality control study of the EORTC Radiotherapy and Lung Cancer Cooperative Groups. <i>European Journal of Cancer & Clinical Oncology</i> , 1991 , 27, 615-9		18
20	Neural cell adhesion molecule expression, neuroendocrine differentiation and prognosis in lung carcinoma. <i>European Journal of Cancer & Clinical Oncology</i> , 1991 , 27, 431-5		69
19	Mitoxantrone in malignant pleural mesothelioma: a study by the EORTC Lung Cancer Cooperative Group. <i>European Journal of Cancer & Clinical Oncology</i> , 1991 , 27, 1627-9		46
18	Polycyclic aromatic hydrocarbon-DNA adducts in lung tissue from lung cancer patients. <i>Carcinogenesis</i> , 1990 , 11, 1677-81	4.6	78
17	Physical and psychosocial consequences of total laryngectomy. <i>Clinical Otolaryngology</i> , 1990 , 15, 421-5	1.8	95
16	K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. <i>New England Journal of Medicine</i> , 1990 , 323, 561-5	59.2	679
15	Aerosol application of interferon-alpha in the treatment of bronchioloalveolar carcinoma. <i>European Journal of Cancer & Clinical Oncology</i> , 1990 , 26, 738-40		23
14	Value of neuron specific enolase in early detection of relapse in small cell lung carcinoma. <i>European Journal of Cancer & Clinical Oncology</i> , 1990 , 26, 373-6		13

13	Toxicity and supportive care in small cell lung cancer: a consensus report. <i>Lung Cancer</i> , 1989 , 5, 146-151	5.9	1
12	Recurrent breast cancer and an adenocarcinoma of the lung occurring in one patient: c-myc oncogene amplification and K-ras codon 12 point mutation as tumour markers. <i>European Journal of Cancer & Clinical Oncology</i> , 1988 , 24, 1529-30		2
11	Lung volume calculations from 81Krm SPECT for the quantification of regional ventilation. <i>Clinical Physics and Physiological Measurement: an Official Journal of the Hospital Physicists Association, Deutsche Gesellschaft Fur Medizinische Physik and the European Federation of Organisations for Medical Physics</i> , 1988 , 9, 147-54		10
10	Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. <i>New England Journal of Medicine</i> , 1987 , 317, 929-35	59.2	455
9	Second primary cancers in the lung in head and neck cancer patients: a challenge. <i>European Journal of Cancer & Clinical Oncology</i> , 1987 , 23, 883-6		17
8	Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy. <i>European Journal of Cancer & Clinical Oncology</i> , 1987 , 23, 1409-11		119
7	The radioprotective effect of N-acetylcysteine in thorax irradiation of mice. <i>Radiotherapy and Oncology</i> , 1987 , 10, 67-9	5.3	13
6	Radiotherapy and cis-diammine dichloroplatinum (II) as a combined treatment modality for inoperable non-small cell lung cancer: a dose finding study. <i>International Journal of Radiation Oncology Biology Physics</i> , 1986 , 12, 379-83	4	29
5	Prevalence of neuroendocrine granules in small cell lung carcinoma. Usefulness of electron microscopy in lung cancer classification. <i>Journal of Pathology</i> , 1986 , 149, 41-7	9.4	15
4	The grey area between small cell and non-small cell lung carcinomas. Light and electron microscopy versus clinical data in 14 cases. <i>Journal of Pathology</i> , 1986 , 149, 49-54	9.4	19
3	N-isopropyl-p[123I]iodoamphetamine, a new agent for lung imaging studies. <i>Thorax</i> , 1986 , 41, 801-3	7.3	12
2	Amiodarone pneumonitis: three further cases with a review of published reports. <i>Thorax</i> , 1984 , 39, 57-64	7.3	51
1	Pulmonary Injury Elicited by Blood: An Experimental Study. <i>European Surgical Research</i> , 1979 , 11, 301-316	1	3